Yiran Gan 9/5/26 Yiran Gan 9/5/26 Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial Read More Yiran Gan 8/22/26 Yiran Gan 8/22/26 Assessing Neurodegenerative Diseases: High-Sensitivity Technologies That Assay Pathological Biomarkers in Blood Read More Yiran Gan 6/24/26 Yiran Gan 6/24/26 Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Severe-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay Read More Yiran Gan 6/23/26 Yiran Gan 6/23/26 Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction Read More Yiran Gan 6/23/26 Yiran Gan 6/23/26 Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia Read More Yiran Gan 6/23/26 Yiran Gan 6/23/26 Using Immunomagnetic Reduction to Assay Reagent Stability of Biomarkers Associated with Alzheimer’s Disease Read More Yiran Gan 6/23/26 Yiran Gan 6/23/26 Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles Read More Yiran Gan 6/23/26 Yiran Gan 6/23/26 Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods Read More Yiran Gan 6/23/26 Yiran Gan 6/23/26 Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia Read More Yiran Gan 6/23/26 Yiran Gan 6/23/26 Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays Read More Older Posts
Yiran Gan 9/5/26 Yiran Gan 9/5/26 Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial Read More
Yiran Gan 8/22/26 Yiran Gan 8/22/26 Assessing Neurodegenerative Diseases: High-Sensitivity Technologies That Assay Pathological Biomarkers in Blood Read More
Yiran Gan 6/24/26 Yiran Gan 6/24/26 Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Severe-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay Read More
Yiran Gan 6/23/26 Yiran Gan 6/23/26 Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction Read More
Yiran Gan 6/23/26 Yiran Gan 6/23/26 Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia Read More
Yiran Gan 6/23/26 Yiran Gan 6/23/26 Using Immunomagnetic Reduction to Assay Reagent Stability of Biomarkers Associated with Alzheimer’s Disease Read More
Yiran Gan 6/23/26 Yiran Gan 6/23/26 Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles Read More
Yiran Gan 6/23/26 Yiran Gan 6/23/26 Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods Read More
Yiran Gan 6/23/26 Yiran Gan 6/23/26 Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia Read More
Yiran Gan 6/23/26 Yiran Gan 6/23/26 Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays Read More
